INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10706742		
Filing Date		2003-11-12		
First Named Inventor Hans		F. van Rietschote		
Art Unit		2187		
Examiner Name Farro		kh, Hashem		
Attorney Docket Number		5760-16400		

U.S.PATENTS							
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	6772231		2004-08-03	Reuter, et al.		
	2	5546558		1996-08-13	Jacobson, et al.		
	3	6985956		2006-01-10	Luke, et al.		
	4	5987565		1999-11-16	Gavaskar		
	5	6763445		2004-07-13	Klein, et al.		
	6	5809285		1998-09-15	Hilland		
	7	6763440		2004-07-13	Traversat, et al.		
	8	6003065		1999-12-14	Yan, et al.		

Application Number 10706742 Filing Date 2003-11-12 INFORMATION DISCLOSURE First Named Inventor Hans F. van Rietschote STATEMENT BY APPLICANT Art Unit 2187 (Not for submission under 37 CFR 1.99) Examiner Name Farrokh Hashem Attorney Docket Number 5780,16400

9	6789103	2004-09-07	Kim, et al.	
10	6370646	2002-04-09	Goodman, et al.	
11	6795966	2004-09-21	Lim, et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

		U.S. PATENT APPLICATION PUBLICATIONS							
Examiner Initial* Cite No Publication		Publication Number		de l Date Name of Patentee of Applicant		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear			
		1	20030110351		2003-06-12	Blood, et al.			
		2	20020069369		2002-06-06	Tremain			
		3	20040010787		2004-01-15	Traut, et al.			

If you wish to add additional U.S. Published Application citation information please click the Add button.

	FOREIGN PATENT DOCUMENTS							
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button

Examiner Initials*	Cite No				
	1				

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE Date Considered

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTID Peter Documents at years. LISPTID, CIDIO or MPEP 901.04. Either office that issued the document, by the burdets code (WIPD Standard ST.3). The dependence of the Counterful Counterful

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10706742
Filing Date		2003-11-12
First Named Inventor	Hans	F. van Rietschote
Art Unit		2187
Examiner Name	Farro	kh, Hashem
Attorney Docket Number		5760-16400

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1,98 to mak	e the appropriate	selection(s):
---------------	----------	-----------------	-------------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication of normal foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement Sea 37 CFR 197(a)(1).

ΩR

That no item of information contained in the Information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and t, the knowledge of the person signing the certification after making reasonable inquity, no item of Information contained in the Information disclosure statement was known to any Individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the Information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Lawrence J Morkel

□ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

41191

Tomic or and digitalians.			
Signature	/Lawrence J. Merkel/	Date (YYYY-MM-DD)	2007-04-06

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fined by the USPTO to process) an application. Confidentially is gowered by \$5.1.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Them will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradentant Office, u.S. operatment of Commence, P. 0.8b 1456, Alexandri, V.S. 22313-1450. DN OTS END FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. 8bx 1450, Alexandria, VA.22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. 2-95-79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is SS U.S.C. 2(b)(2); (2) furnishing of the information solicided is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademark Office is to process and/or examine you submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine you submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient o

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act
 (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the
 Department of Justice to determine where the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodistrions.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursulant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designe, cuting an inspection of records concluded by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make.
- 3. A record from this system of records may be disclosed, as a routine use, be the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public insepticions or an insuce of partner.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.